Compare ASRT & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASRT | NSRX |
|---|---|---|
| Founded | 1995 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.1M | 63.4M |
| IPO Year | 1997 | 2025 |
| Metric | ASRT | NSRX |
|---|---|---|
| Price | $11.38 | $7.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $35.00 | $20.50 |
| AVG Volume (30 Days) | ★ 69.5K | 9.2K |
| Earning Date | 11-10-2025 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $137,354,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.22 | N/A |
| 52 Week Low | $7.71 | $5.90 |
| 52 Week High | $15.15 | $9.99 |
| Indicator | ASRT | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 87.55 | N/A |
| Support Level | $9.11 | N/A |
| Resistance Level | $10.39 | N/A |
| Average True Range (ATR) | 0.61 | 0.00 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 91.03 | 0.00 |
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.